@article{JGO12162,
author = {Emmanuel Gabriel and Shipra Gandhi and Kristopher Attwood and Boris Kuvshinoff and Steven Hochwald and Renuka Iyer},
title = {Gemcitabine and capecitabine for advanced biliary cancer},
journal = {Journal of Gastrointestinal Oncology},
volume = {8},
number = {4},
year = {2017},
keywords = {},
abstract = {Background: Gemcitabine with capecitabine (gem-cap) is an established regimen for advanced biliary cancer (ABC) supported by our previously reported phase II trial. Here, we provide our updated experience.
Methods: Single institution, retrospective study from 2005 to 2015 of ABC treated with gem-cap.
Results: A total of 372 patients with ABC were identified, of whom 227 (61.0%) were treated with chemotherapy. 153 patients (67.4%) received gem-cap, of which 129 (56.8%) received it in the first line. Thirty two point six percent (42/129) were locally advanced, 67.4% (87/129) had metastatic disease, and 18.6% (24/129) received it as adjuvant therapy. Disease sites included 48.8% [63] intrahepatic cholangiocarcinoma (IHCC), 24.0% [31] extrahepatic cholangiocarcinoma (EHCC) and 27.1% [35] gallbladder carcinoma (GBC). Median follow-up was 49.7 months (mo). The median PFS and OS were 8.0 mo [95% confidence intervals (CI): 6.0–9.3] and 13.0 mo (95% CI: 10.7–17.4), respectively. Overall, 53.5% (69/129) experienced a grade 3/4 toxicity. The most common (35.7%) was a hematologic toxicity (neutropenia or thrombocytopenia) followed by infection (25.6%).
Conclusions: Gem-cap provides similar survival outcomes to gemcitabine/cisplatin based on historical comparison to the ABC-2 trial (median PFS =8.0 mo and OS =11.7 mo). Gem-cap may offer the advantage of fewer adverse events compared to the levels reported in ABC-2 (grade 3/4 events 70.7%).},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/12162}
}